The dramatic upregulation of αvβ3-integrin that occurs in the vasculature during tumor growth has long suggested that the endothelial expression of this molecule is an ideal target for antiangiogenic therapy to treat cancer. This discovery led to the development of small-molecule inhibitors directed against αvβ3-integrin that are currently in clinical trials. In 2002, we reported that β3-integrin−knockout mice exhibit enhanced tumor growth and angiogenesis. However, as β3-integrin is expressed by a wide variety of cells, endothelial cell-specific contributions to tumor angiogenesis are muddied by the use of a global knockout of β3-integrin function.
I n order to grow and metastasize, solid tumors must recruit their own blood supply from the surrounding vasculature. This process, called angiogenesis, is initiated when the hypoxic tumor begins to release angiogenic growth factors, such as vascular endothelial growth factor (VEGF). New blood vessel formation follows in a step-wise fashion with the removal of supporting cells (pericytes) from the existing nearby capillary vasculature and the degradation of the endothelial cell basement membrane and extracellular matrix. Endothelial cells begin to proliferate and migrate toward the tumor. These latter processes are dependent on integrins. 1 
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Integrins are heterodimeric transmembrane extracellular matrix receptors composed of an α-and a β-subunit.
2 αvβ3-Integrin is expressed by endothelial cells on stimulation with angiogenic growth factors, and its expression is dramatically upregulated in tumor vasculature at sites of inflammation and tissue repair. [3] [4] [5] Ligation of αvβ3-integrin induces endothelial cell proliferation, survival, and migration. In addition, αvβ3-integrin and VEGF receptor 2 (VEGFR2) interact synergistically in endothelial cells to promote angiogenesis. 6 These findings indicate a proangiogenic role for αvβ3-integrin, which correlates with its enhanced expression by tumor vasculature. As such, αvβ3-integrin has become an attractive antiangiogenic target for the development of antagonists. β3-Integrin blockade using antibodies, Arg-Gly-Asp (RGD) peptide antagonists, or signaling-defective mutants results in reduced tumor growth and angiogenesis. 4, [7] [8] [9] In contrast, however, genetic ablation studies suggest an antiangiogenic role for αvβ3-integrin. β3-Integrin-knockout mice exhibit enhanced tumor growth and angiogenesis that is associated with an upregulation of VEGFR2 expression and signaling. 10, 11 Furthermore, β3-integrin expression limits the contribution that neuropilin-1 (a VEGF coreceptor) makes to VEGF-induced angiogenesis, thereby inhibiting the process. 12 Based on knockout and inhibition studies, a combination of pro-and antiangiogenic roles have been assigned to β3-integrin. One limitation of both approaches is, however, the global level at which the analyses have taken place. β3-Integrin expression is not restricted to neovascular endothelial cells. It is expressed on platelets and megakaryocytes (where it plays a critical role in platelet aggregation) and by pericytes and bone marrow-derived cells (BMDCs), all of which may contribute to angiogenesis (see Robinson and Hodivala-Dilke 13 for a recent review). Bone marrow transplantation studies, for example, have clearly demonstrated that the absence of β3-integrin expression in BMDCs in β3-integrin-knockout animals contributes to the enhanced tumor growth in this model. 14, 15 We present here a dissection of the contribution made specifically by endothelial β3-integrin to tumor growth and angiogenesis. The knowledge gained from these studies is key to understanding the basic biology behind the dramatic vascular upregulation of this molecule during neoangiogeneis and, more impotantly, to improving the design of therapeutic strategies that target the expression of the molecule. The current strategies have proven to be somewhat disappointing with many tumors either not responding to or becoming resistant to β3-integrin-directed therapy. 16 Because this is of such fundamental importance, we have re-evaluated the function of β3-integrin in tumor angiogenesis by crossing β3-floxed mice 17 to 2 different endothelial-specific Cre lines-lines we have used separately in the past to elucidate the role of other endothelial integrins 18, 19 and focal adhesion kinase (FAK) 20 in tumor angiogenesis. Tie1Cre 21 constitutively depletes floxed targets in endothelial cells, thereby creating a cell-specific mimic of a global knockout, whereas Pdgfb-iCreER T2 (see Claxton et al 22 ) depletes floxed targets in endothelial cells in a 4-hydroxy-tamoxifen (OHT)-inducible fashion (a model more akin to antagonist administration). We have used these mice to analyze growth and angiogenesis in subcutaneous syngeneic tumor models, as well as in ex vivo and in vitro angiogenic assays.
Methods

Animals
A detailed description of the mice used in this study can be found in the Methods section in the Online Data Supplement. All animals were on a mixed C57BL6/129 background. Littermate controls were used for all in vivo experiments. All animal experiments were performed in accordance with UK Home Office regulations and the European Legal Framework for the protection of animals used for scientific purposes (European Directive 86/609/EEC).
In Vivo Tumor Growth Assay
Syngeneic mouse tumor cell lines, B16F0 (melanoma, derived from C57BL6) and CMT19T (lung carcinoma, derived from C57BL6), were used in subcutaneous tumor growth experiments as described elsewhere. 20 Detailed parameters can be found in the Online Data Supplement.
Immunohistochemical Analysis
Histological analyses were performed as described previously. 23 Antibodies used and detailed staining parameters can be found in the Online Data Supplement.
Mouse Tumor Endothelial Cell Isolation
PECAM1-positive cells were isolated from enzymatically digested tumors by magnetic activated cell sorting. Detailed parameters can be found in the Online Data Supplement.
Mouse Lung Endothelial Cell Isolation and Culture
Lung microvascular endothelial cells (LuECs) were isolated and cultured as described elsewhere. 12 Detailed parameters can be found in the Online Data Supplement.
Ex Vivo Aortic Ring Assays
Thoracic aortae were isolated from 6-to 9-week-old adult mice and prepared for culture as described previously. 24 VEGF assays were performed in collagen, fibroblast growth factor assays in fibrin. Where indicated, VEGF or fibroblast growth factor was added at 30 ng/mL. Microvessel growth on aortic rings was quantified after 6 to 10 days. After maximum sprouting capacity was achieved, aortic rings were fixed and stained with FITC-IB4 lectin and visualized by epifluorescence.
Bone Marrow Isolation
BMDCs were isolated by flushing femurs of β3-floxed/Tie1Cre-negative/positive animals or from 15-day, OHT-treated β3-floxed/ Pdgfb-iCreER T2 -negative/positive mice with PBS. Cells were passed through a 70-µm mesh and collected by centrifugation at 1500 rpm for 5 minutes. Red blood cells were lyzed in Red Blood Lysis buffer (eBioscience) for 5 minutes. Cells were resupended in PBS containing 1% fetal bovine serum and plated in a 96-well plate (5×10 5 cells per well). Cells were incubated with directly conjugated antibodies for 30 minutes at 4°C. After washing, analysis was performed on a BD Accuri C6 flow cytometer. Antibodies used were FITC-anti-CD45 (1:200; eBiosciene); Alexa Flour 488-anti-CD184 (1:200; eBiosciene); and PE-anti-CD61 (1:200; eBioscience).
Platelet Isolation
Peripheral blood was collected from β3-floxed/Tie1Cre-negative/ positive animals or from 15-day, OHT-treated β3-floxed/PdgfbiCreER T2 -negative/positive animals in tubes containing anticoagulant buffer (38 mmol/L citric acid, 75 mmol/L sodium citrate, 100 mmol/L dextrose). Blood samples were centrifuged for 10 minutes at 100g. The resulting platelet-rich plasma was transferred to a fresh tube and centrifuged for 10 minutes at 400g. The final pellet was lyzed in electrophoresis sample buffer and processed for Western blot analysis.
Flow Cytometry
LuECs were analyzed as described previously. 25 Antibodies used and detailed staining parameters can be found in the Online Data Supplement.
Western Blot Analysis
Western blot analysis was performed as described previously. 20 Antibodies used and detailed staining parameters can be found in the Online Data Supplement.
Adhesion Assays
These assays were performed as described previously. 10 
Wound Closure Assay
In vitro scratch wound assays were performed as described previously. 12 Detailed parameters can be found in the Online Data Supplement.
Statistical Analysis
Significant differences between means were evaluated by Student t test. P<0.05 was considered statistically significant.
Results
Tumor Growth and Angiogenesis Are Inhibited in β3-Floxed/Pdgfb-iCreER T2 Animals, but Not in β3-Floxed/Tie1Cre Animals To our surprise, the effects on tumor growth and angiogenesis in the 2 Cre models differed significantly from β3-knockout animals. Tie1Cre-mediated long-term depletion of endothelial β3-integrin did not significantly affect growth or angiogenesis of either B16F0 or CMT19T tumor cells ( Figure 1A ) after 12 days. Whereas, OHT-induced acute depletion of the protein via Pdgfb-iCreER T2 inhibited growth and angiogenesis in both tumor models ( Figure 1B) . On a detailed histological analysis of tumor sections, we observed no changes in tumor vessel pericyte or basement membrane coverage (Online Figure IA) , or in overall vessel distribution across tumors (Online Figure IB) , when drawing comparisons between Cre-negative and Cre-positive animals, or between the 2 Cre models. We also analyzed vessel perfusion in thick (vibratome) sections from CMT19T tumors (B16F0 tumors are too soft for vibratome sectioning). Vessel patency (as measured by intravenous injection of PE-labeled anti-PECAM1) was limited to a thin ring around the outer perimeter of the tumor (Online Figure IC) and was of a similar depth in β3-floxed/ Tie1Cre-negative, β3-floxed/Tie1Cre-positive, and β3-floxed/ Pdgfb-iCreER T2 -negative animals. Patent vessels penetrated deeper in β3-floxed/Pdgfb-iCreER T2 -positive tumors, but this could be attributed to their much smaller size (ie, these tumors have not yet established a poorly vascularized core). We then extended our analyses of the 2 Cre models by examining microvessel sprouting from aortic rings. VEGF-induced sprouting (measured on day 6) was significantly enhanced on Tie1Cre-mediated depletion of β3-integrin and inhibited on its Pdgfb-iCreER T2 -mediated depletion ( Figure 1C ). One possible explanation for the difference between the 2 models is the nonendothelial-specific (leaky) expression of the 2 promoters used to drive Cre expression. The Pdgfb promoter can be expressed in megakaryocytes, 22 but we did not observe any changes in platelet levels of β3-integrin in either Cre line (Online Figure IIA) . Furthermore, β3-floxed/ Pf4Cre (a platelet-specific Cre) 27 mice do not show any significant effects on tumor growth. 17 More importantly, Tie1 is expressed by a small proportion (≈20%) of BMD hematopoietic cell lineages 21 (as opposed to other constitutive endothelial-specific Cre models, such as Tie2Cre, which is reportedly expressed in ≈80%). 28 We examined β3-integrin expression in BMDCs from both Cre models. Although we saw no changes in β3-integrin in BMDCs of OHT-treated Pdgfb-iCreER T2 -positive animals, Tie1Cre-positive animals showed a loss of β3-integrin expression in CD45 + cells (CD45 is a PAN marker for hematopoietic cells, including hematopoietic progenitor/ stem cells but excluding erythrocytes and platelets; Online Figure IIB ). Tie1Cre-positive animals did not, however, show loss of β3-integrin expression in CXCR4 (CD184)-expressing cells. The majority of BMDCs recruited to angiogenic sites express CXCR4, and the loss of β3-integrin expression in these cells would be expected to impinge on tumor angiogenesis. 29 We speculated that the absence of β3-integrin depletion in CXCR4 + cells (primarily macrophages) 29 explains why, unlike β3-integrin-knockout mice, β3-floxed/Tie1Cre-positive mice do not exhibit enhanced tumor growth and angiogenesis in vivo. We examined this by performing flow cytometry on whole tumor homogenates from β3-floxed/Tie1Cre-positive and -negative animals. Our speculation was supported by the fact that we saw no changes in β3-integrin levels in F4/80-positive tumor-associated macrophages from β3-floxed/ Tie1Cre-positive animals (Online Figure IIC) .
Some Cellular and Molecular Differences Occur Between the 2 Cre Models
It is possible that phenotypic differences between the 2 Cre models are a result of variances in molecular compensation arising from either long-or short-term β3-integrin depletion. This prompted us to examine endothelial cell (EC) characteristics in greater detail. We isolated LuECs from β3-floxed/ Tie1Cre animals and from β3-floxed/Pdgfb-iCreER T2 animals that were treated with OHT in vivo for 15 days before isolation and compared their biological and molecular characteristics in vitro. Although they showed an expected defect in adhesion to vitronectin, Cre-positive LuECs from both models showed adhesion to fibronectin, collagen type I, and laminin-I that was comparable to their Cre-negative counterparts (Online Figure IIIA) . Using flow cytometric analysis (Figure 2A ), we showed that surface expression of β3-integrin was depleted to similar levels in Cre-positive cells from both models. α1-, α5-, αv-, and β1-integrin subunit levels were similar in all cells, whereas α2-integrin levels seemed to decrease in Cre-positive cells from both models (note, however, that the levels of α1-and α2-integrin were particularly low in all cells). Although we were unable to detect surface expression of β5-integrin in our cultured ECs, Western blot analysis showed a decrease in total levels of this integrin subunit in β3-floxed/Tie1Cre-positive LuECs, but not in β3-floxed/ Pdgfb-iCreER T2 LuECs ( Figure 2A ). We saw no changes in overall LuEC survival in culture (not shown), so we next examined VEGF-induced migration, an essential feature of EC behavior that is mediated by integrins, by performing wound closure assays. Acute depletion of β3-integrin inhibited wound closure, whereas long-term depletion had no effect (Online Figure IIIB) . Because we continued to observe some differences between the 2 Cre models, we decided to investigate in detail VEGF-mediated signaling. We first examined VEGFR2 expression and phosphorylation. Neither Cre model elicited changes in total levels of VEGFR2 expression ( Figure 2B ). However, acute depletion of β3-integrin led to a reduction in VEGF-induced VEGFR2 phosphorylation, whereas no changes were noted on long-term depletion of β3-integrin ( Figure 2B ). Another important function of αvβ3-integrin is the regulation of VEGFR2 recycling back to the cell surface, 30 so we examined surface expression of VEGFR2 by flow cytometry. We observed a small but significant increase in surface expression of VEGFR2 in β3-floxed/Tie1Cre-positive LuECs compared with their Cre-negative controls ( Figure 2C ). This small increase was similar to that noted in β3-integrin-null LuECs when they are compared with wildtype LuECs ( Figure 2C ). No changes occurred in β3-floxed/ Pdgfb-iCreER T2 -positive LuECs. To examine a wide spectrum of signaling pathways simultaneously, LuECs were stimulated with VEGF, and protein lysates were put onto PathScan Intracellular Signaling Arrays. The only signaling molecule to show any change between Cre-negative and Cre-positive animals (in both models) was ERK1/2 (not shown). We, therefore, examined VEGF-induced ERK1/2 phosphorylation in greater detail in cultured LuECs and showed that, compared with Cre-negative controls, ERK1/2 phosphorylation was enhanced in β3-floxed/Tie1Cre-positive LuECs, but suppressed in β3-floxed/Pdgfb-iCreER T2 -positive LuECs ( Figure 2D ).
However, this kit did not include many important angiogenic signaling components, so we analyzed other VEGF-induced signaling molecules by Western blot analyses. Given our β5-integrin findings and the known link between αv-integrins and VEGF-dependent migration-associated molecules, such as Src and FAK, [31] [32] [33] we focused mainly on this pathway. We Figure 2 . Characterization of endothelial cells isolated from Tie1Cre and Pdgfb-iCreER T2 lines. A, Representative flow cytometric profiles for α1-, α2-, α5-, αv-, β1-, and β3-integrin subunit expression levels on the indicated lung microvascular endothelial cells (LuECs). Isotype-matched profiles are shown as controls (black). β5-Integrin expression was analyzed by Western blot. HSC70 is shown as a loading control. Bar chart represents the mean (±SEM) densitometric quantification of total β5-integrin levels over multiple experiments (n≥3) shown relative to Tie1Cre-negative cells. B, Western blot analysis of vascular endothelial growth factor receptor 2 (VEGFR2) phosphorylation in LuECs. Cells were stimulated with 30 ng/mL VEGF for 5 minutes. Protein lysates were Western blotted for phosphorylated VEGFR2 (pVEGFR2; Y1175) and subsequently reblotted for total VEGFR2 (tVEGFR2). Data are representative of 3 independent experiments; 2 separate lysates are shown. Bar chart represents the mean (±SEM) densitometric quantification of pVEGFR2 levels relative to non-VEGF-treated cells (fold stimulation) over multiple experiments. C, Representative flow cytometric profiles of VEGFR2 expression levels on LuECs. IgG isotype control is shown as a control (black). D, Western blot analysis of ERK1/2 phosphorylation in LuECs. Cells were stimulated with 30 ng/mL VEGF for the indicated times. Protein lysates were Western blotted for phosphorylated ERK1/2 (pERK) and subsequently reblotted for total ERK1/2 (tERK). Data are representative of 4 independent experiments. Bar chart represents the mean (±SEM) densitometric quantification of pERK levels relative to non-VEGF-treated cells (fold stimulation) over multiple experiments. Values have been normalized to tERK levels. Hashed lines demarcate baseline and 2-fold stimulation levels.
observed a reduction in the levels of phosphorylated and total FAK in β3-floxed/Tie1Cre-positive LuECs (Online Figure  IIIC) . However, consistent with our PathScan findings, we saw no changes in p38 phosphorylation, which is also associated with this pathway. We, therefore, examined other players in the αv-integrin-FAK pathway, such as mTOR, S6 Ribosomal Protein (p70S6K), and PDK-1. 34 The PathScan array showed no changes in mTOR or p70S6K, nor did we observe any changes in PDK-1 phosphorylation by Western blot (Online Figure IIIC) . Finally, we examined responses to fibroblast growth factor in both LuECs and aortic rings. We observed no differences in ERK1/2 phosphorylation (Online Figure IVA) nor in aortic ring sprouting (Online Figure IVB) , suggesting that the responses described above are, at least partially, VEGF-specific.
Pattern of Cre Activity and Efficiency of β3-Integrin Depletion Are Similar in the 2 Endothelial Cre Models
Multiple other possibilities may explain the dichotomous effects we observed between the 2 Cre models. We examined each of these in turn and noted no significant differences when comparing: (1) VEGFR2 expression levels ( Figure 3A -3C and as noted in Figure 2B ). This was important to examine at multiple levels because a global deletion of β3-integrin can lead to the upregulation of endothelial VEGFR2 expression, 11 and changes in VEGFR2 expression levels might have explained differences in VEGF responses when comparing the 2 Cre models; (2) the efficiency of Cre-induced β3-integrin depletion. We showed this by both Western blot analyses ( Figure 3A-3C ) and in whole tumors ( Figure 3D) ; (3) the pattern of Cre activity (as measured by tomato Cre reporter activity) 35 in the experimental models we used ( Figure 3E and 3F). The Pdgfb promoter, in particular, may be highly active in endothelial tip cells, specialized cells found at the leading edge of angiogenic sprouts that are highly motile, 36 and differences in Cre activity between the 2 models in this population of cells (and hence differences in β3-integrin depletion) could explain differential effects on angiogenic responses. 37 However, we saw no differences in the distribution of Cre activity when comparing the 2 models in aortic rings; Cre was active in both tip and stalk cells in both Tie1Cre and Pdgfb-iCreER T2 rings ( Figure 3F ). Taking these findings in sum, we concluded that the length of time β3-integrin had been depleted was the major factor determining the angiogenic response and dictating the differences observed between our 2 endothelial Cre models.
Pdgfb-iCreER T2 Model Behaves Like the Tie1Cre Model if the Time of β3-Integrin Depletion Is Extended by Longer OHT Treatment
Given that the models differ in the amount of time that β3-integrin has been depleted, we extended the time of OHT treatment of Pdgfb-iCreER T2 animals before allograft administration to determine whether β3-floxed/Pdgfb-iCreER T2 mice would behave more like β3-floxed/Tie1Cre mice. We saw no effect on tumor growth or angiogenesis when tumor cell administration was preceded by 21 days of OHT treatment (for a total of 33 days of OHT treatment, henceforth referred to as long OHT). The inhibitory effects previously observed with acute depletion of endothelial β3-integrin (OHT administered 3 days before allograft administration, for a total of 15 days of treatment, henceforth referred to as short OHT) were completely abrogated ( Figure 4A) . A reciprocal loss of angiogenic inhibition was also observed in aortic rings derived from β3-floxed/Pdgfb-iCreER T2 -positive long OHT animals ( Figure 4B) . A side-by-side comparison of tumor growth in the 3 models illustrated similar growth kinetics of CMT19T tumor cells in β3-floxed/Tie1Cre and β3-floxed/Pdgfb-iCreER T2 long OHT mice; only in β3-floxed/Pdgfb-iCreER T2 -positive short OHT animals was tumor growth inhibited ( Figure 4C ). We conclude that by disrupting β3-integrin well before tumor induction, β3-floxed/Pdgfb-iCreER T2 animals behave like β3-floxed/Tie1Cre animals, and more importantly, there is a complete loss of preventive benefit with long-term depletion of endothelial β3-integrin.
Further Characterization of Angiogenesis in β3-Floxed/Pdgfb-iCreER
T2 Long OHT Animals Uncovers Commonalities With β3-Floxed/Tie1Cre Animals
We next examined many of the parameters noted above in LuECs isolated from β3-floxed/Pdgfb-iCreER T2 mice treated for 33 days in vivo with OHT. When comparing β3-floxed/PdgfbiCreER T2 -positive long OHT LuECs with their Cre-negative counterparts, we noted similar changes to those observed in β3-floxed/Tie1Cre-positive LuECs: (1) only defects in adhesion to vitronectin (Online Figure VA) ; (2) no change in VEGFinduced wound closure (Online Figure VB) ; (3) unaltered levels of integrin subunit surface expression, but a reduction in total levels of β5-integrin expression ( Figure 5A ); (4) no changes in VEGF-mediated VEGFR2 phosphorylation, but an increase in expression of VEGFR2 at the cell surface ( Figure 5B) ; and (5) no alterations in VEGF-induced ERK1/2 phosphorylation ( Figure 5C ). Additionally, we examined pericyte and basement coverage of tumor vessels, as well as vessel distribution and patency and noticed no overt differences between long OHT Cre-negative and Cre-positive animals (Online Figure VI) . We speculate that long-term depletion of β3-integrin, regardless of the Cre driving the depletion, leads to common mechanisms of escape from the otherwise inhibitory effects of interfering with the endothelial expression of this molecule.
We recently showed that a 50% reduction in FAK expression in FAK-heterozygous mice leads to enhanced tumor growth and angiogenesis. 23 FAK-heterozygous ECs display an imbalance in FAK phosphorylation at Y397 and Y861, which suggests a potential role for FAK as a nonlinear, dose-dependent regulator of angiogenesis. Therefore, we next examined changes in FAK expression and phosphorylation in our β3-floxed/Cre models in greater detail. Western blot analysis indicated that total FAK levels were reduced by ≈50% in β3-floxed/Tie1Cre-positive and β3-floxed/Pdgfb-iCreER Figure 6B ). These findings suggest that prolonged suppression of endothelial β3-integrin leads to a reduction in FAK expression and a misbalance in FAK phosphorylation that helps circumvent the inhibitory effects mediated by the loss of β3-integrin.
Tumor Growth and Angiogenesis Are Not Inhibited by β3-Integrin Depletion in Already Established Tumors
Finally, we extended our analyses with the Pdgfb-iCreER T2 (short OHT) line to more clinically relevant models of tumor growth.
Prolonging the growth of CMT19T allografts by an additional 6 days (still within their exponential growth phase) in PdgfbiCreER T2 -depleted mice negated the inhibitory effects observed at day 12 ( Figure 7A ). We could not extend treatment of B16F0 allografts, because these tumors grow extremely rapidly beyond day 12 and reach a plateau phase of growth by day 13 or 14.
To test the effects of β3-integrin disruption in tumors with established vasculature, we used an intervention treatment scheme. This scheme mimics the common clinical situation of treating patients with established tumors and evaluating effects on tumor progression. B16F0 or CMT19T tumor cells were implanted subcutaneously and OHT was administered T2 animals that were pretreated with 4-hydroxy-tamoxifen (OHT) for 21 days before allograft administration (see inset for scheme). Fresh OHT treatment was started at the time of allograft injection (for a total of 33 days of OHT treatment; long OHT). Twelve-day-old tumor volumes showed no statistical difference between Cre-negative and Cre-positive littermates (left). Bar chart shows mean tumor volume (±SEM). Representative pictures of tumor macroscopic appearances are shown. Representative Western blot analysis of endothelial cells (ECs) isolated from CMT19T tumors grown in long OHT-treated β3-floxed/Pdgfb-iCreER T2 mice (middle). HSC70 acts as a loading control. Blood vessel density was assessed by counting the total number of endomucin-positive vessels per mm 2 across entire tumor sections (right). Bar chart shows mean vessel number per mm 2 (±SEM). Data are representative of 3 independent experiments, where n=5 mice per genotype per experiment. B, Microvessel sprouting of aortic ring explants isolated from long OHT-treated β3-floxed/Pdgfb-iCreER T2 mice was stimulated with vascular endothelial growth factor (VEGF). Unstimulated rings were used as a negative control. Bar chart shows total number of microvessel sprouts per aortic ring (mean±SEM) after 6 days of VEGF stimulation (in the continued presence of 1 µmol/L OHT). Data are representative of 3 experiments where n≥20 rings per genotype per experiment. Representative micrographs of FITC-IB4 (an endothelial cell marker)-stained aortic rings (bottom). Scale bar, 0.5 mm. C, Direct comparison of CMT19T tumor growth in the 3 models. Tumor cells were injected subcutaneously in β3-floxed/TieCre mice, β3-floxed/Pdgfb-iCreER T2 mice pretreated for 3 days with OHT (for a total of 15 days; short OHT), and β3-floxed/Pdgfb-iCreER T2 mice pretreated for 21 days with OHT (for a total of 33 days; long OHT). Bar chart shows mean tumor volume (±SEM) as measured externally by calipers over time. Also shown is the mean tumor weight in micrograms (±SEM) at the end of the experiment. n≥5 animals per genotype; **P<0.01; nsd, no significant difference (unpaired 2-tailed t test). after 8 days. Tumor volumes were assessed 5 and 10 days later. Although substantial β3-integrin depletion was achieved in TECs, no significant differences were observed between β3-floxed/Pdgfb-iCreER T2 -negative and -positive animals at day 13 (B16F0 tumors had to be harvested at this stage for the reasons described above; see Online Figure VIII ) or day 18 ( Figure 7B) . We also used an intervention strategy in the aortic ring neoangiogenesis assay by inducing β3-integrin depletion in aortic rings derived from β3-floxed/Pdgfb-iCreER T2 animals after microvessel sprouting had already begun (3 days after their embedding and VEGF stimulation). Sprouts were then counted at day 8. Cre activity was established <24 hours (as measured by tomato Cre reporter activity), yet no significant differences were observed in the degree of sprouting when comparing Crenegative aortic rings with Cre-positive aortic rings ( Figure 7C ).
Discussion
β3-Integrin-knockout mice exhibit a complex phenotype that includes enhanced pathological angiogenesis. However, as mentioned above, β3-integrin is expressed by a diverse set of cells, and the described phenotype must arise from the integration of its pattern of expression. Although interesting, this Figure 5 . Further characterization of the long 4-hydroxy-tamoxifen (OHT)-treated Pdgfb-iCreER T2 lung endothelial cells. A, Representative flow cytometric profiles for α1-, α2-, α5-, αv-, β1-, and β3-integrin subunit expression levels on long OHT-treated lung microvascular endothelial cells (LuECs). Isotype-matched profiles are shown as controls (black). β5-Integrin expression was analyzed by Western blot. HSC70 is shown as a loading control. Bar chart represents the mean (±SEM) densitometric quantification of total β5-integrin levels over multiple experiments (n≥3) shown relative to Cre-negative cells. B, Western blot analysis of vascular endothelial growth factor receptor 2 (VEGFR2) phosphorylation in long OHT-treated LuECs (left). Cells were stimulated with 30 ng/mL of VEGF for 5 or 60 minutes. Protein lysates were Western blotted for phosphorylated VEGFR2 (pVEGFR2; Y1175) and subsequently reblotted for total VEGFR2 (tVEGFR2). Data are representative of 3 independent experiments. Representative flow cytometric profile of VEGFR2 expression levels on long OHT-treated LuECs. IgG isotype control is shown as a control (black; right). C, Western blot analysis of ERK1/2 phosphorylation in long OHT-treated LuECs. Cells were stimulated with 30 ng/mL VEGF for the indicated times. Protein lysates were Western blotted for phosphorylated ERK1/2 (pERK) and subsequently reblotted for total ERK1/2 (tERK). Data are representative of 3 independent experiments. Bar chart represents the mean (±SEM) densitometric quantification of pERK levels relative to non-VEGF-treated cells (fold stimulation) over multiple experiments. Values have been normalized to tERK levels. Hashed lines demarcate baseline and 2-fold stimulation levels. *P<0.05; **P<0.01; nsd, no significant difference (unpaired 2-tailed t test). Note that no OHT was present during the culturing of cells; β3-integrin depletion was induced before isolation.
biological integration makes it difficult to distinguish cell autonomous effects of β3-integrin. Our studies have addressed, for the first time to our knowledge, the specific contribution that endothelial β3-integrin makes to tumor growth and angiogenesis. Our findings have profound implications for targeting the endothelial-specific expression of β3-integrin to inhibit tumor angiogenesis, a strategy that is growing in popularity with the maturation of nanotechnology. 38 Consistent with our findings in β3-knockout animals, 10 the depletion of endothelial β3-integrin did not alter the structure of established tumor vessels (Online Figure IA and Online Figure  VIA) . Sprouting angiogenesis involves an initial increase in EC proliferation, migration, and tube formation, followed by maturation of vessels that includes the recruitment of supporting cells and the deposition of an intact basement. Because we show deposition of a nidogen-rich basement membrane and the number of tumor vessels with associated αSMA-positive supporting cells is normal when endothelial β3-integrin is depleted (in both Cre models), we interpret our data to indicate that β3-integrin supports the initial phases of neovascularization. This conclusion is buttressed by 2 key findings: (1) genetic inhibition of endothelial β3-integrin is ineffective in an intervention strategy (once angiogenesis is in full swing, β3-integrin is not required; Figure 7B and 7C); (2) acute depletion of β3-integrin inhibited LuEC migration (athough not, notably, cell survival; Online Figure IIIB) .
The αvβ3-integrin antagonist studies, which show the potential to inhibit angiogenesis both in vitro 39 and in vivo 16, [40] [41] [42] when targeting the molecule, have always stood in seeming contrast to the enhanced angiogenesis observed in β3-integrinknockout mice. The findings we present here help to marry the conflicting results and, more importantly, to explain further the disappointing clinical outcomes achieved to date with αvβ3-integrin antagonism. Our studies indicate that the timing of endothelial β3-integrin targeting is critical. As mentioned above, β3-integrin depletion does not inhibit tumor growth or angiogenesis when applied in an intervention type scheme ( Figure 7B and 7C). Furthermore, early preventive benefit of β3-integrin depletion (which likely results from decreased interactions between αvβ3-integrin and VEGR2, leading to reduced VEGFR2 phosphorylation; Figure 2B ) is lost over time ( Figure 7A ), an effect that is most pronounced with long-term depletion of the molecule, as demonstrated by β3-floxed/Tie1Cre animals and long OHT-treated β3-floxed/Pdgfb-iCreER T2 animals. By performing a detailed comparison, we have identified common changes that occur within the ECs of these 2 models: (1) increased surface expression of VEGFR2; (2) decreased total expression of β5-integrin; and (3) decreased expression (and misbalanced phosphorylation) of FAK. At least 1 of these alterations mimics what occurs in β3-knockout cells (altered surface expression of VEGFR2; Figure 2C ). However, unlike the β3-integrin-knockout studies, long-term depletion of endothelial β3-integrin does not result in enhanced pathological angiogenesis in vivo, thus emphasizing that the increased tumor growth that occurs in β3-integrin-knockout mice is primarily a result of β3-integrin deletion in nonendothelial cells. 14, 15, 29 Tumorassociated macrophages seem to be unaltered in their levels of β3-integrin expression in β3-floxed/Tie1Cre-positive animals.
Any one of the changes we have identified might contribute to an escape from angiogenic inhibition directed at β3-integrin (in fact, it may be a sum of these and other changes that contribute to escape). For example, canstatin, an endogenous inhibitor of angiogenesis derived from the α2 chain of type IV collagen, binds αvβ5-integrin leading to activation in ECs of an apoptotic program. 43 With reduced levels of this integrin, a natural pathway that keeps angiogenesis in check has been removed. We chose to pursue the FAK findings in greater detail because of our recent publication of the FAK-heterozygous phenotype. However, there are differences. Unlike what we observed in the FAK-heterozygous studies, here we see no changes in Akt phosphorylation, which has been linked to the phenotype in FAK-heterozygous animals. 23 This suggests that the changes in Akt in FAK-heterozygous mice arise through a non-EC-autonomous route. No doubt, there are other changes occurring in our Cre models that have yet to be identified, which will help explain, for example, why Tie1Cre-mediated depletion of β3-integrin enhances angiogenic responses ex vivo, whereas long OHT-treated Pdgfb-iCreER T2 -mediated depletion does not. Importantly, our findings parallel disappointing clinical studies showing similar results with long-term pharmacological inhibition of αvβ3-integrin. 16, 44 In a recent phase III trial, Cilengitide (an RGD peptide antagonist of αvβ3-integrin and, to a lesser degree, of αvβ5-integrin) did not meet its primary end point of significantly increasing overall survival when added to the current standard chemoradiotherapy regimen. 45 This outcome suggests that we do not yet have the necessary knowledge or understanding of how best to use this promising antiangiogenic agent. We have shown previously that the dose of αvβ3-integrin antagonist achieved in vivo is important in the regulation of angiogenesis, a finding that illustrated the need to gain a more thorough understanding of how different doses of αvβ3-integrin-directed agents regulate angiogenesis. 25 Here, we show that the length of time endothelial αvβ3-integrin is inhibited may also be critical to angiogenic responses.
The studies we present here suggest that current αvβ3-integrin-directed strategies need refinement. This is a goal worth pursuing. Unlike current Food and Drug Administrationapproved antiangiogenic drugs, αvβ3-integrin antagonists seem to be well tolerated, 46 likely because of the fact that the vascular expression of αvβ3-integrin is restricted to neoangiogenic vessels. In contrast, the targets of other antiangiogenic drugs are expressed in nearly all adult vascular endothelial cells, 47 and these drugs (especially those with broadspectrum activity) are linked with significant side effects, such as renal toxicity, bleeding, arterial thromboembolic events, wound healing complications, and gastrointestinal perforation, as well as vessel regression in several healthy tissues. Our next aim, then (using the models we have created), is to determine how mechanisms of escape that occur with endothelial β3-integrin inhibition can be circumvented, and to determine how these mechanisms can be targeted safely and effectively in combination with new or existing αvβ3-integrin antagonists to improve therapeutic outcomes.
